OCCLUNOVA – AN IMPLANTABLE DEVICE FOR CHRONIC ATRIAL FIBRILLATION
Founded by NLC, OccluNova is developing an implantable LAA closure device for people with chronic atrial fibrillation (AF) Atrial fibrillation (AF) affects 4.5 million people in Europe and more than 3 million in the US. It has seen a 33% rise over the last 20 years and almost 12 million people in the US alone […]